Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 400 Shares

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 400 shares of Capricor Therapeutics stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $30.00, for a total value of $12,000.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $336,690. This represents a 3.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Anthony Bergmann also recently made the following trade(s):

• On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $15,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total value of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Price Performance

NASDAQ:CAPR traded down $0.09 during trading hours on Wednesday, reaching $29.51. 803,008 shares of the stock were exchanged, compared to its average volume of 955,468. Capricor Therapeutics, Inc. has a twelve month low of $4.30 and a twelve month high of $40.37. The firm has a 50 day moving average of $30.26 and a 200 day moving average of $28.40. The stock has a market cap of $1.71 billion, a PE ratio of -12.72 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Equities research analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. Creek Drive Management Group LLC bought a new position in Capricor Therapeutics during the fourth quarter worth about $1,039,000. Moody Aldrich Partners LLC acquired a new position in Capricor Therapeutics during the fourth quarter worth approximately $6,025,000. Pier Capital LLC raised its stake in Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after buying an additional 128,837 shares during the period. UBS Group AG raised its stake in Capricor Therapeutics by 91.0% in the fourth quarter. UBS Group AG now owns 238,216 shares of the biotechnology company’s stock valued at $6,875,000 after buying an additional 113,499 shares during the period. Finally, HBK Sorce Advisory LLC lifted its position in shares of Capricor Therapeutics by 19.4% in the fourth quarter. HBK Sorce Advisory LLC now owns 203,705 shares of the biotechnology company’s stock valued at $5,879,000 after buying an additional 33,128 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CAPR. Piper Sandler restated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Roth Mkm reiterated a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a report on Friday, May 15th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. B. Riley Financial raised their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.36.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.